NASDAQ:MYOK - MyoKardia Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$47.70 -0.55 (-1.14 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$47.70
Today's Range$46.30 - $48.05
52-Week Range$12.20 - $62.83
Volume228,361 shs
Average Volume386,282 shs
Market Capitalization$1.74 billion
P/E Ratio-34.07
Dividend YieldN/A
Beta3.66

About MyoKardia (NASDAQ:MYOK)

MyoKardia logoMyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio4.63
Quick Ratio4.63

Price-To-Earnings

Trailing P/E Ratio-34.07
Forward P/E Ratio-27.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.50 million
Price / Sales76.26
Cash FlowN/A
Price / CashN/A
Book Value$6.04 per share
Price / Book7.90

Profitability

EPS (Most Recent Fiscal Year)($1.40)
Net Income$-45,950,000.00
Net Margins-235.47%
Return on Equity-25.18%
Return on Assets-20.76%

Miscellaneous

Employees102
Outstanding Shares35,970,000

MyoKardia (NASDAQ:MYOK) Frequently Asked Questions

What is MyoKardia's stock symbol?

MyoKardia trades on the NASDAQ under the ticker symbol "MYOK."

How were MyoKardia's earnings last quarter?

MyoKardia (NASDAQ:MYOK) announced its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.21. The biotechnology company earned $5.33 million during the quarter, compared to analysts' expectations of $7.82 million. MyoKardia had a negative net margin of 235.47% and a negative return on equity of 25.18%. View MyoKardia's Earnings History.

What price target have analysts set for MYOK?

6 equities research analysts have issued 1 year target prices for MyoKardia's stock. Their forecasts range from $54.00 to $83.00. On average, they expect MyoKardia's share price to reach $69.50 in the next year. View Analyst Ratings for MyoKardia.

Who are some of MyoKardia's key competitors?

Who are MyoKardia's key executives?

MyoKardia's management team includes the folowing people:
  • Mr. Tassos Anastasios Gianakakos, CEO, Pres & Director (Age 45)
  • Mr. Jake B. Bauer, Chief Bus. Officer (Age 39)
  • Dr. Marc Semigran M.D., Chief Medical Officer (Age 61)
  • Dr. Charles J. Homcy, Advisor (Age 70)
  • Dr. Eric J. Topol, Advisor (Age 64)

Has MyoKardia been receiving favorable news coverage?

Press coverage about MYOK stock has trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. MyoKardia earned a news impact score of 0.01 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.80 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are MyoKardia's major shareholders?

MyoKardia's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.02%), Farallon Capital Management LLC (2.89%), Foresite Capital Management III LLC (1.09%), Fernwood Investment Management LLC (0.78%), Wells Fargo & Company MN (0.69%) and Northern Trust Corp (0.67%). Company insiders that own MyoKardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr, Rock Ventures Ii LP Third, Sanofi and Wendy L Yarno. View Institutional Ownership Trends for MyoKardia.

Which major investors are selling MyoKardia stock?

MYOK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Citadel Advisors LLC, Iguana Healthcare Management LLC, Eversept Partners LLC and HarbourVest Partners LLC. Company insiders that have sold MyoKardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr and Rock Ventures Ii LP Third. View Insider Buying and Selling for MyoKardia.

Which major investors are buying MyoKardia stock?

MYOK stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Foresite Capital Management III LLC, UBS Group AG, Eventide Asset Management LLC, Victory Capital Management Inc., Hershey Trust Co., Fernwood Investment Management LLC and WINTON GROUP Ltd. Company insiders that have bought MyoKardia stock in the last two years include Sanofi and Wendy L Yarno. View Insider Buying and Selling for MyoKardia.

How do I buy shares of MyoKardia?

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MyoKardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $47.70.

How big of a company is MyoKardia?

MyoKardia has a market capitalization of $1.74 billion and generates $22.50 million in revenue each year. The biotechnology company earns $-45,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. MyoKardia employs 102 workers across the globe.

How can I contact MyoKardia?

MyoKardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]


MarketBeat Community Rating for MyoKardia (MYOK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  263
MarketBeat's community ratings are surveys of what our community members think about MyoKardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MyoKardia (NASDAQ:MYOK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for MyoKardia in the last 12 months. Their average twelve-month price target is $69.50, suggesting that the stock has a possible upside of 45.70%. The high price target for MYOK is $83.00 and the low price target for MYOK is $54.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $69.50$66.6667$55.6667$55.00
Price Target Upside: 45.70% upside32.67% upside5.83% upside13.75% upside

MyoKardia (NASDAQ:MYOK) Consensus Price Target History

Price Target History for MyoKardia (NASDAQ:MYOK)

MyoKardia (NASDAQ:MYOK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2018CowenReiterated RatingBuy$73.00HighView Rating Details
4/13/2018Wells Fargo & CoReiterated RatingOutperform$70.00MediumView Rating Details
3/9/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $83.00HighView Rating Details
3/9/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $68.00HighView Rating Details
3/9/2018WedbushBoost Price TargetOutperform$51.00 ➝ $69.00HighView Rating Details
12/12/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$54.00MediumView Rating Details
(Data available from 5/26/2016 forward)

Earnings

MyoKardia (NASDAQ:MYOK) Earnings History and Estimates Chart

Earnings by Quarter for MyoKardia (NASDAQ:MYOK)

MyoKardia (NASDAQ:MYOK) Earnings Estimates

2018 EPS Consensus Estimate: ($2.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.41)($0.41)($0.41)
Q2 20181($0.57)($0.57)($0.57)
Q3 20181($0.66)($0.66)($0.66)
Q4 20181($0.72)($0.72)($0.72)

MyoKardia (NASDAQ MYOK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.29)($0.50)$7.82 million$5.33 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.41)($0.21)$5.63 million$5.60 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.42)($0.42)$6.10 million$5.63 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.41)$6.73 million$5.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.36)($0.37)$7.00 million$5.60 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.18)$0.44$3.55 million$28.60 millionViewN/AView Earnings Details
11/7/2016Q316($0.07)($0.35)$4.83 million$3.55 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.37)$3.55 million$3.55 millionViewN/AView Earnings Details
5/12/2016Q1($0.53)($0.32)$3.55 million$3.55 millionViewN/AView Earnings Details
3/18/2016Q4($0.68)($0.48)$3.55 million$3.55 millionViewN/AView Earnings Details
11/18/2015Q3 2015($2.78)$3.55 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MyoKardia (NASDAQ:MYOK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MyoKardia (NASDAQ MYOK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.40%
Institutional Ownership Percentage: 83.90%
Insider Trading History for MyoKardia (NASDAQ:MYOK)
Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)

MyoKardia (NASDAQ MYOK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/4/2018Anastasios GianakakosCEOSell3,000$47.57$142,710.0074,968View SEC Filing  
5/3/2018Jake BauerInsiderSell1,519$48.95$74,355.0562,125View SEC Filing  
4/11/2018Jake BauerInsiderSell5,000$50.00$250,000.0066,777View SEC Filing  
4/4/2018Anastasios GianakakosInsiderSell3,000$47.95$143,850.0077,390View SEC Filing  
3/26/2018Jake BauerInsiderSell164$50.95$8,355.8061,941View SEC Filing  
3/5/2018Anastasios GianakakosInsiderSell3,000$61.07$183,210.0077,390View SEC Filing  
2/26/2018Anastasios GianakakosInsiderSell5,000$60.00$300,000.0079,390View SEC Filing  
2/5/2018Anastasios GianakakosInsiderSell3,000$51.05$153,150.0077,390View SEC Filing  
1/12/2018Joseph LambingInsiderSell5,000$50.00$250,000.0095,846View SEC Filing  
1/9/2018Jake BauerInsiderSell5,000$45.00$225,000.0056,777View SEC Filing  
1/4/2018Anastasios GianakakosInsiderSell3,000$41.70$125,100.00512,117View SEC Filing  
1/3/2018Kevin P StarrDirectorSell816,326$42.00$34,285,692.00View SEC Filing  
1/2/2018Jake BauerInsiderSell5,000$42.89$214,450.0062,877View SEC Filing  
12/21/2017Anastasios GianakakosInsiderSell3,000$41.09$123,270.00512,117View SEC Filing  
11/6/2017Anastasios GianakakosCEOSell4,300$40.23$172,989.00513,417View SEC Filing  
10/4/2017Anastasios GianakakosInsiderSell4,300$40.86$175,698.00View SEC Filing  
10/3/2017Kevin P StarrDirectorSell75,313$40.28$3,033,607.64View SEC Filing  
9/26/2017Kevin P StarrDirectorSell601,400$43.00$25,860,200.00View SEC Filing  
9/26/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell400,000$43.00$17,200,000.00View SEC Filing  
9/25/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell201,400$43.00$8,660,200.00View SEC Filing  
9/11/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell221,250$41.30$9,137,625.00View SEC Filing  
9/8/2017Kevin P StarrDirectorSell201,250$41.01$8,253,262.50View SEC Filing  
9/5/2017Anastasios GianakakosInsiderSell4,300$43.02$184,986.00512,463View SEC Filing  
8/22/2017Joseph LambingInsiderSell5,000$45.00$225,000.0099,718View SEC Filing  
8/15/2017Joseph LambingInsiderSell5,000$40.00$200,000.00104,718View SEC Filing  
8/14/2017SanofiMajor ShareholderBuy350,000$35.50$12,425,000.00View SEC Filing  
8/14/2017Wendy L YarnoDirectorBuy1,408$35.50$49,984.001,408View SEC Filing  
8/8/2017Joseph LambingInsiderSell15,000$30.00$450,000.00119,718View SEC Filing  
8/7/2017Jake BauerInsiderSell15,000$28.33$424,950.0075,545View SEC Filing  
8/4/2017Anastasios GianakakosCEOSell4,300$16.62$71,466.00512,463View SEC Filing  
7/25/2017Anastasios GianakakosInsiderSell32,988$15.00$494,820.00541,151View SEC Filing  
3/20/2017Anastasios GianakakosCEOSell1,412$15.00$21,180.00509,454View SEC Filing  
3/20/2017Jake BauerInsiderSell667$15.00$10,005.0083,900View SEC Filing  
10/3/2016SanofiMajor ShareholderBuy450,000$15.00$6,750,000.00View SEC Filing  
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00482,165View SEC Filing  
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00239,190View SEC Filing  
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.0025,408View SEC Filing  
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MyoKardia (NASDAQ MYOK) News Headlines

Source:
DateHeadline
Q2 2018 EPS Estimates for MyoKardia (MYOK) Lifted by WedbushQ2 2018 EPS Estimates for MyoKardia (MYOK) Lifted by Wedbush
www.americanbankingnews.com - May 24 at 7:56 AM
MyoKardia prices common stock offeringMyoKardia prices common stock offering
seekingalpha.com - May 23 at 8:41 AM
MyoKardias (MYOK) Buy Rating Reiterated at CowenMyoKardia's (MYOK) Buy Rating Reiterated at Cowen
www.americanbankingnews.com - May 22 at 9:18 PM
Zacks: Analysts Anticipate MyoKardia (MYOK) Will Post Quarterly Sales of $6.32 MillionZacks: Analysts Anticipate MyoKardia (MYOK) Will Post Quarterly Sales of $6.32 Million
www.americanbankingnews.com - May 22 at 1:54 AM
MyoKardia finalizes design of late-stage study of mavacamten in oHCM; shares down 9%MyoKardia finalizes design of late-stage study of mavacamten in oHCM; shares down 9%
seekingalpha.com - May 21 at 4:53 PM
BRIEF-MyoKardia Says Offering 3.75 Mln Common SharesBRIEF-MyoKardia Says Offering 3.75 Mln Common Shares
www.reuters.com - May 21 at 4:53 PM
BRIEF-MyoKardia Says Phase 3 Explorer-Hcm Study Evaluating Mavacamten To Initiate In Q2 2018BRIEF-MyoKardia Says Phase 3 Explorer-Hcm Study Evaluating Mavacamten To Initiate In Q2 2018
www.reuters.com - May 21 at 8:42 AM
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic CardiomyopathyMyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
finance.yahoo.com - May 21 at 8:42 AM
MyoKardia (MYOK) Expected to Post Earnings of -$0.46 Per ShareMyoKardia (MYOK) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - May 20 at 11:16 PM
Should You Buy MyoKardia Inc (NASDAQ:MYOK) At $50.55?Should You Buy MyoKardia Inc (NASDAQ:MYOK) At $50.55?
finance.yahoo.com - May 19 at 8:41 AM
MyoKardia (MYOK) Receives Consensus Recommendation of "Buy" from AnalystsMyoKardia (MYOK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 14 at 5:31 PM
Q2 2018 Earnings Forecast for MyoKardia Issued By Wedbush (MYOK)Q2 2018 Earnings Forecast for MyoKardia Issued By Wedbush (MYOK)
www.americanbankingnews.com - May 14 at 2:03 AM
MyoKardia (MYOK) Downgraded to "Sell" at BidaskClubMyoKardia (MYOK) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - May 12 at 7:35 AM
MyoKardia (MYOK) Downgraded to Hold at Zacks Investment ResearchMyoKardia (MYOK) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 11 at 12:49 PM
FY2022 EPS Estimates for MyoKardia (MYOK) Reduced by AnalystFY2022 EPS Estimates for MyoKardia (MYOK) Reduced by Analyst
www.americanbankingnews.com - May 11 at 11:52 AM
MyoKardia (MYOK) Doses First Patient in PIONEER Open-Label Extension Study of MavacamtenMyoKardia (MYOK) Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten
www.streetinsider.com - May 10 at 5:22 PM
Extension study underway for MyoKardias mavacamtenExtension study underway for MyoKardia's mavacamten
seekingalpha.com - May 10 at 5:22 PM
MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceMyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 10 at 5:22 PM
MyoKardia (MYOK) Upgraded to "Buy" by Zacks Investment ResearchMyoKardia (MYOK) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - May 10 at 4:23 PM
BRIEF-MyoKardia Doses First Patient In Pioneer Open-Label Extension Study Of MavacamtenBRIEF-MyoKardia Doses First Patient In Pioneer Open-Label Extension Study Of Mavacamten
www.reuters.com - May 10 at 8:56 AM
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic CardiomyopathyMyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
finance.yahoo.com - May 10 at 8:56 AM
Edited Transcript of MYOK earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of MYOK earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:56 AM
MyoKardia (MYOK) Issues  Earnings Results, Misses Estimates By $0.21 EPSMyoKardia (MYOK) Issues Earnings Results, Misses Estimates By $0.21 EPS
www.americanbankingnews.com - May 9 at 1:43 PM
Myokardias (MYOK) CEO Jack Clem on Q1 2018 Results - Earnings Call TranscriptMyokardia's (MYOK) CEO Jack Clem on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:51 AM
MyoKardia: 1Q Earnings SnapshotMyoKardia: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:51 AM
MyoKardia misses by $0.21, misses on revenueMyoKardia misses by $0.21, misses on revenue
seekingalpha.com - May 8 at 5:07 PM
MyoKardia Reports First Quarter 2018 Financial ResultsMyoKardia Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 5:07 PM
Form 4 MyoKardia Inc For: May 04 Filed by: GIANAKAKOS ANASTASIOSForm 4 MyoKardia Inc For: May 04 Filed by: GIANAKAKOS ANASTASIOS
www.streetinsider.com - May 8 at 8:47 AM
MyoKardia (MYOK) CEO Anastasios Gianakakos Sells 3,000 SharesMyoKardia (MYOK) CEO Anastasios Gianakakos Sells 3,000 Shares
www.americanbankingnews.com - May 7 at 10:26 PM
Jake Bauer Sells 1,519 Shares of MyoKardia (MYOK) StockJake Bauer Sells 1,519 Shares of MyoKardia (MYOK) Stock
www.americanbankingnews.com - May 7 at 7:56 PM
$7.82 Million in Sales Expected for MyoKardia (MYOK) This Quarter$7.82 Million in Sales Expected for MyoKardia (MYOK) This Quarter
www.americanbankingnews.com - May 5 at 3:39 AM
MyoKardia (MYOK) Expected to Announce Earnings of -$0.28 Per ShareMyoKardia (MYOK) Expected to Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - May 3 at 6:17 PM
MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018
finance.yahoo.com - May 3 at 4:58 PM
MyoKardia (MYOK) to Release Quarterly Earnings on MondayMyoKardia (MYOK) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 2 at 8:32 PM
MyoKardia (MYOK) Receives Consensus Recommendation of "Buy" from BrokeragesMyoKardia (MYOK) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 19 at 5:40 PM
-$0.28 Earnings Per Share Expected for MyoKardia (MYOK) This Quarter-$0.28 Earnings Per Share Expected for MyoKardia (MYOK) This Quarter
www.americanbankingnews.com - April 16 at 9:21 AM
Wells Fargo Reiterates "Outperform" Rating for MyoKardia (MYOK)Wells Fargo Reiterates "Outperform" Rating for MyoKardia (MYOK)
www.americanbankingnews.com - April 13 at 10:37 AM
Jake Bauer Sells 5,000 Shares of MyoKardia (MYOK) StockJake Bauer Sells 5,000 Shares of MyoKardia (MYOK) Stock
www.americanbankingnews.com - April 12 at 10:10 PM
BMO Capital Markets Reiterates Buy Rating for MyoKardia (MYOK)BMO Capital Markets Reiterates Buy Rating for MyoKardia (MYOK)
www.americanbankingnews.com - April 12 at 5:09 PM
Myokardia (MYOK) Upgraded by Zacks Investment Research to "Hold"Myokardia (MYOK) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 7 at 12:39 AM
Insider Selling: Myokardia Inc (MYOK) Insider Sells 3,000 Shares of StockInsider Selling: Myokardia Inc (MYOK) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - April 5 at 10:20 PM
MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial OfficerMyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer
finance.yahoo.com - April 4 at 8:51 AM
MyoKardia commences mid-stage study of mavacantem in non-obstructive HCMMyoKardia commences mid-stage study of mavacantem in non-obstructive HCM
seekingalpha.com - April 2 at 5:03 PM
MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy PatientsMyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
finance.yahoo.com - April 2 at 5:03 PM
Edited Transcript of MYOK earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of MYOK earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - April 1 at 8:49 AM
 Brokerages Expect Myokardia Inc (MYOK) Will Announce Quarterly Sales of $7.82 Million Brokerages Expect Myokardia Inc (MYOK) Will Announce Quarterly Sales of $7.82 Million
www.americanbankingnews.com - April 1 at 4:02 AM
Myokardia (MYOK) Downgraded by Zacks Investment ResearchMyokardia (MYOK) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM
 Analysts Expect Myokardia Inc (MYOK) Will Post Earnings of -$0.28 Per Share Analysts Expect Myokardia Inc (MYOK) Will Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - March 30 at 1:21 PM
Myokardia (MYOK) Stock Rating Upgraded by BidaskClubMyokardia (MYOK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 26 at 8:56 AM
Myokardia Inc (MYOK) Receives Average Recommendation of "Buy" from BrokeragesMyokardia Inc (MYOK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 5:30 PM

SEC Filings

MyoKardia (NASDAQ:MYOK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MyoKardia (NASDAQ:MYOK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MyoKardia (NASDAQ MYOK) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.